Health Care & Life Sciences » Biotechnology | Heat Biologics Inc.

Heat Biologics Inc.

Heat Biologics Inc.
Stock Exchange NASDAQ Stock Market
Market Cap
$23.51 M
Shares Outstanding
34.07 M
Public Float
29.66 M


801 Capitola Drive
Durham North Carolina 27713
United States
Employees -
Updated 07/08/2019
Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The firm's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the firm's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers.


View All

Jeff A. Wolf
Chairman, President & Chief Executive Officer
John James Monahan
Independent Director